ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2163

Predictors of Patient Engagement and Usability in a Chronic Musculoskeletal Pain Management App

Marc Blanchard1, Cinja Koller2, Patrick Hermann1, Johanna Mettler1, Tiffany Prétat3, Pedro Ming Azevedo3 and Thomas Hügle3, 1Lausanne University Hospital, Lausanne, Vaud, Switzerland, 2Doctoral School, Faculty of Biology and Medicine, University of Lausanne, Genève, Vaud, Switzerland, 3Lausanne University Hospital, Lausanne, Switzerland

Meeting: ACR Convergence 2024

Keywords: fibromyalgia, Outcome measures, pain, Patient reported outcomes

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Patient Outcomes, Preferences, & Attitudes Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Mobile health apps have demonstrated effectiveness in managing chronic musculoskeletal pain syndromes such as fibromyalgia. We developed an app called POCOS for chronic musculoskeletal pain management, focusing on a patient-centered design. Understanding the relationship between patient interaction with the app and their clinical and demographic characteristics is essential for refining these tools and enhancing personalized digital health strategies. This study aims to explore the clinical and demographic prognostic factors in patient profiles for engagement in a mobile health app for chronic pain management.

Methods: A test version of POCOS was released for iOS and Android, with participants recruited from a multimodal care program for chronic musculoskeletal pain. Patients underwent various assessments such as for fibromyalgia, alexithymia, pain disability, psychiatric conditions or medication. Over four weeks, we collected usability metrics and patient-reported outcomes through the app, with patients being weekly reminded to use the app via SMS.

Results: POCOS was presented to 44 patients. Of those, 28 (64%) accepted to use it and participate in the study, with 24 (55%) finally downloading the app and 22 (50%) actively using it. The cohort was 82% female with a mean age of 46.1 ± 10.5 years. Among users, 91% fulfilled ACR criteria for fibromyalgia, 86.4% had depression, 18.2% anxiety, 13.6% Post Traumatic Syndrome Disorder (PTSD), mean Wide Spread Index (WPI) was 12.0, and mean Symptom Severity Scale (SSS) was 8.36; 26.3% exhibited alexithymia. Intermediate analysis shows significant correlations between cumulative app use and opiate medication (r = 0.57, p < 0.01) and PTSD (r = 0.55, p < 0.01). Depression was negatively correlated with app use (r = -0.47, p < 0.05). No significant correlations were observed with sex, age, BMI, FiRST (Fibromyalgia Rapid Screening Tool), WPI, and SSS scores. App use and virtual reality session efficacy for pain reduction showed a marginally significant correlation (r = 0.40, p = 0.07). A strong significant correlation was observed between the number of completed health forms and app usage, indicating high compliance in patient reported outcomes documentation (0.84). Recruitment and data collection are ongoing.

Conclusion: This study highlights how clinical and demographic factors influence engagement with the POCOS app for chronic pain management. Positive correlations between app usage and conditions such as PTSD or opioid medication use suggest these patients benefit from such approaches. However, the negative association with depression indicates challenges in engaging these individuals. These findings underscore the need to tailor digital health interventions to individual patient profiles for optimal engagement and outcomes. Future research with a larger cohort will clarify these relationships and guide the refinement of personalized digital health strategies for chronic pain management.

Supporting image 1

Figure 1: Heatmap illustrating correlations between clinical factors (e.g., opiate medication, depression) and app usage in chronic pain management (POCOS).

Supporting image 2

Figure 2: Cumulative app activations per POCOS user over the first month period


Disclosures: M. Blanchard: ATREON SA, 4; C. Koller: None; P. Hermann: ATREON SA, 12, Shareholder; J. Mettler: None; T. Prétat: None; P. Ming Azevedo: None; T. Hügle: AbbVie/Abbott, 6, ATREON SA, 4, GlaxoSmithKlein(GSK), 6, Novartis, 6, Roche, 6.

To cite this abstract in AMA style:

Blanchard M, Koller C, Hermann P, Mettler J, Prétat T, Ming Azevedo P, Hügle T. Predictors of Patient Engagement and Usability in a Chronic Musculoskeletal Pain Management App [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/predictors-of-patient-engagement-and-usability-in-a-chronic-musculoskeletal-pain-management-app/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-patient-engagement-and-usability-in-a-chronic-musculoskeletal-pain-management-app/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology